CompletedNCT05750043
Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan
Studying Onchocerciasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Universiteit Antwerpen
- Principal Investigator
- Jane Carter, MDAmref Health Africa
- Intervention
- bi-annual CDTI(drug)
- Enrollment
- 17000 enrolled
- Eligibility
- All sexes
- Timeline
- 2018 – 2023
Study locations (1)
- Amref Health Africa, Juba, Central, South Sudan
Collaborators
Amref Health Africa
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05750043 on ClinicalTrials.govOther trials for Onchocerciasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06350851Development of a New Rapid Diagnostic Test to Support Onchocerciasis EliminationBioaster
- ACTIVE NOT RECRUITINGPHASE2NCT05180461Emodepside Phase II Trial for Treatment of OnchocerciasisDrugs for Neglected Diseases
- ACTIVE NOT RECRUITINGPHASE3NCT03876262Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for OnchocerciasisMedicines Development for Global Health